ALNYLAM PHARMACEUTICALS INC

NASDAQ: ALNY (Alnylam Pharmaceuticals, Inc.)

Last update: yesterday, 7:09PM

149.40

-7.10 (-4.54%)

Previous Close 156.50
Volume 2,517,029
Price / Earnings (Forward) 12.24
Price / Sales 4.30
Price / Book 5.81
52 Weeks Range
147.58 (-1%) — 479.79 (221%)
Profit Margin -11.49%
Operating Margin (TTM) 3.04%
Diluted EPS (TTM) -2.11
Quarterly Revenue Growth (YOY) 20.20%
Total Debt/Equity (MRQ) 2,358.25%
Current Ratio (MRQ) 3.04
Operating Cash Flow (TTM) -45.11 M
Levered Free Cash Flow (TTM) 223.09 M
Return on Assets (TTM) -1.79%

AIStockmoo Score

-1.7
Neutral for 2 days
Earns below its cost of capital. Returns on capital rising. info
High debt. Weak profitability. Ample short-term liquidity. Positive cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
Downtrend over the past year. Far below its 52-week high. info
In a downtrend: the price is below its moving averages, and they are falling. It has dropped well below them. Volume is heavier on down days. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Recent news mixed or neutral. info
Holdings' Sentiment info NA
Insiders net selling recently. info
Institutions net +1.62% of shares in their latest 13F filings: 407 holders increased, 416 decreased (quarter to 30 Sep 2026). info
Short interest -13.8% from 31 Aug to 30 Oct 2026, 1.9 days to cover (FINRA). info
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
Earnings per share have risen every year. Made a loss in recent years. info
Below its medium-term trend line. info
Price is low against its 52-week average. Down over 5 years. info
Trend down on all three terms. Short-term momentum falling. info
Price is near support. Levels trending down. info
Final Score -1.75
Show all

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Alnylam Pharmaceuticals, Inc. Mixed Bearish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
ALNY - - - 5.81 -1.7
BMRN - - - 1.81 -0.2
VRTX - - - 6.50 1.1
WVE 536 M - - 1.36 -2.3
ONC - - - 8.10 0.8
RPRX - 1.37% - 4.48 0.8

Select this tab to load the latest available analysis.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam’s commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Sector Healthcare
Industry Biotechnology
Investment Style Mid Growth
% Held by Insiders 3.81%
% Held by Institutions 97.56%

No data within this time range.

Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
GREENSTREET YVONNE - 165.04 -11,000 -1,815,440
PYOTT DAVID E I - - 0 0
SCHULMAN AMY W 156.61 - 1,910 299,125
SIGAL CHARLES ELLIOTT 151.64 - 1,600 242,624
Aggregate Net Quantity -7,490
Aggregate Net Value ($) -1,273,691
Aggregate Avg. Buy ($) 154.34
Aggregate Avg. Sell ($) 165.04
Insider Range ($)
151.64 (1%) — 165.04 (10%)
Name Holder Date Type Quantity Price Value ($)
GREENSTREET YVONNE Officer 13 Nov 2026 Disposed (-) 11,000 165.04 1,815,440
SIGAL CHARLES ELLIOTT Director 10 Nov 2026 Buy (+) 1,600 151.64 242,624
PYOTT DAVID E I Director 10 Nov 2026 Option execute 3,780 - -
SCHULMAN AMY W Director 09 Nov 2026 Buy (+) 1,910 156.61 299,125

Institutions

Institutional ownership: 114.25%

Positions Holders Shares
Increased 407 20,577,006
Decreased 416 15,752,895
New 93 909,012
Sold out 149 3,562,413

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 5,465,979 1.9
15 Oct 2026 6,568,786 5.1
30 Sep 2026 7,711,495 6.5
15 Sep 2026 7,194,097 4.1
31 Aug 2026 6,340,087 3.9
14 Aug 2026 4,770,978 2.4

FINRA short interest via Nasdaq, reported twice a month.

3 Positive 2 Negative 7 Neutral
Date Type Details
17 Nov 2026 Yahoo Finance Alnylam Stock Trades Below Its Pre-$1 Billion Buyback Price
Today's big story: Could Nvidia Stock Fall 50%? Follow The Cash.
16 Nov 2026 Yahoo Finance What Is Driving Alnylam Stock?
For questions about this article or underlying research, email [email protected].
12 Nov 2026 Yahoo Finance What Moved Alnylam Stock?
For questions about this article or underlying research, email [email protected].
10 Nov 2026 Yahoo Finance Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD
CAMBRIDGE, Mass., November 10, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its collaborator, Regeneron Pharmaceuticals, Inc. shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of…
09 Nov 2026 Yahoo Finance Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM
CAMBRIDGE, Mass., November 09, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the American Heart Association (AHA) Scientific Sessions 2026, adding to the robust body of evidence demonstrating the strength of RNAi-powered TTR…
06 Nov 2026 Yahoo Finance Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.
04 Nov 2026 Yahoo Finance Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership
CAMBRIDGE, Mass., November 04, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its Board of Directors has authorized a $1 billion share repurchase program and that the Company will transition to new commercial leadership as it enters…
04 Nov 2026 Yahoo Finance Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., November 04, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026, at 10:00 a.m. GMT (5:00 a.m. ET)…
03 Nov 2026 Yahoo Finance What Could Alnylam Pharmaceuticals (ALNY) Five Year HELIOS B Data Change?
Alnylam Pharmaceuticals (NasdaqGS:ALNY) plans to present five-year HELIOS-B data on AMVUTTRA at major medical meetings in 2026. The company will share long-term efficacy and safety findings from the pivotal HELIOS-B trial at the American Heart Association congress. Alnylam also intends to present…
03 Nov 2026 Yahoo Finance Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026
CAMBRIDGE, Mass., November 03, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9 in Chicago…
02 Nov 2026 Yahoo Finance Should You Buy The Dip In Alnylam Stock?
For questions about this article or underlying research, email [email protected].
02 Nov 2026 Yahoo Finance Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience
AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter.
Show more

Technical Setup Medium

Trend order
Slope
Entry –
Volume
In a downtrend: the price is below its moving averages, and they are falling. It has dropped well below them. Volume is heavier on down days.
Nearest support: 146.69 – 151.67 · moderate level
Nearest resistance: 153.51 – 158.49 · moderate level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria